<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04410367</url>
  </required_header>
  <id_info>
    <org_study_id>BED-Flc-219</org_study_id>
    <nct_id>NCT04410367</nct_id>
  </id_info>
  <brief_title>Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)</brief_title>
  <acronym>PURSUE</acronym>
  <official_title>An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blue Earth Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Precision For Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Blue Earth Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish
      Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in
      Detecting Recurrent Brain Metastases After Radiation Therapy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Positron Emission Tomography (PET) Imaging study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual image interpretation criteria</measure>
    <time_frame>1 Year</time_frame>
    <description>To establish visual image interpretation criteria for 18F fluciclovine PET in detecting recurrent and residual brain metastases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of 18F fluciclovine</measure>
    <time_frame>60 days</time_frame>
    <description>Sensitivity of 18F fluciclovine PET for detecting recurrent or residual brain metastases compared to surgical pathology on a patient level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of 18F fluciclovine</measure>
    <time_frame>60 days</time_frame>
    <description>Specificity of 18F fluciclovine PET for detecting recurrent or residual brain metastases compared to surgical pathology on a patient level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as classified by MedDRA</measure>
    <time_frame>60 days</time_frame>
    <description>Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F fluciclovine throughout the study period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous administration of 18F fluciclovine for PET Scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F fluciclovine</intervention_name>
    <description>18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus</description>
    <arm_group_label>Patients</arm_group_label>
    <other_name>Axumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, or 2 if this is
             an acute deterioration

          2. Karnofsky performance score ≥60

          3. Previous history of solid tumor brain metastasis of any origin

          4. Histopathological confirmation of the primary solid tumor or a metastatic site

          5. Previous radiation therapy of brain metastatic lesion(s)

          6. A reference lesion considered by the site investigator to be equivocal for recurrent
             brain metastasis

          7. Patient requires further confirmatory diagnostic procedures to confirm brain MRI
             findings and is planned for craniotomy

        Exclusion Criteria:

        1. Patients with a history of active hematological malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Medical Director</last_name>
    <phone>+441865784186</phone>
    <email>contact@blueearthdx.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Residual Brain Metastases</keyword>
  <keyword>Recurrent Brain Metastases</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Positron Emission Tomography (PET) Scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

